Showing 2321-2330 of 3568 results for "".
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I
- Study: Brepocitinib Reduces Inflammatory Markers in Cicatricial Alopeciahttps://practicaldermatology.com/news/study-brepocitinib-reduces-inflammatory-markers-in-cicatricial-alopecia/2471712/A recent phase 2a clinical trial showed brepocitinib was associated with a significant reduction in C-C motif chemokine ligand 5 (CCL5) expression and improved clinical severity scores in patients with cicatricial alopecia (CA).
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- Analysis: Strontium Cream Reduces Pruritus in Hidradenitis Suppurativa Patientshttps://practicaldermatology.com/news/analysis-strontium-cream-reduces-pruritus-in-hidradenitis-suppurativa-patients/2471630/Topical strontium cream significantly alleviates pruritus in patients with hidradenitis suppurativa (HS), according to a recent study published in the Journal of Clinical and Aesthetic Dermatology.
- Dr. Desai Reflects on AAD's Progress Over Past Yearhttps://practicaldermatology.com/news/Dr-Desai-Reflects-AAD-Progress-Over-Past-Year/2471547/Seemal Desai, MD, FAAD, achieved his dream and propelled the profession forward during his year as American Academy of Dermatology (AAD) president, but work remains to be done, he said in his farewell address at the 2025 AAD Annual Meeting in Orlando, Florida. “This year as your president
- Evolving Approaches to Treating Melasma Highlighted at AADhttps://practicaldermatology.com/news/Evolving-Approaches-Treating-Melasma-Highlighted-AAD/2471546/Use of imaging and aggressive treatment are critical in the medical management of melasma in 2025, Mukta Bhardwaj Sachdev,MD, IFAAD, said at the 2025 American Academy of Dermatology (AAD) Annuel Meeting in Orlando, Florida. “You need to use imaging systems, monitor your patients, [use] top